

PANTHEON-II: The peripheral effects of prednisolone on glucose metabolism, metabolic hormones, insulin sensitivity and insulin secretion in healthy young males and males with metabolic syndrome: a randomised, placebo controlled, double blind, dose-response, parallel group intervention study

Submission date 08/05/2007	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 03/07/2007	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 17/04/2019	Condition category Nutritional, Metabolic, Endocrine	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Michaela Diamant

Contact details
Department of Endocrinology/Diabetes Centre
Vrije University Medical Centre
De Boelelaan 1117
Amsterdam
Netherlands
1081 HV

Additional identifiers

Protocol serial number

Study information

Scientific Title

PANTHEON-II: The peripheral effects of prednisolone on glucose metabolism, metabolic hormones, insulin sensitivity and insulin secretion in healthy young males and males with metabolic syndrome: a randomised, placebo controlled, double blind, dose-response, parallel group intervention study

Acronym

PANTHEON-II

Study objectives

Glucocorticoids (GCs), like prednisolone, are the most commonly prescribed anti-inflammatory and immunosuppressive drugs. Although GCs display excellent efficacy in a great number of (auto-immune) diseases, the side effect profile often limits their therapeutical benefit. Major side effects associated with GC treatment include changes in glucose, lipid and protein metabolism, leading to adult onset (a.o.) insulin resistance, glucose intolerance, muscle wasting and dyslipidemia. Currently a renewed interest exists in these poorly understood diabetogenic side effects, with the development of so called 'dissociated glucocorticoid receptor activators', which seem to be lacking these deleterious effects. With this trial, we expect to obtain results that will aid the development of such compounds by a pharmaceutical company that is involved in this study project. This novel class of drugs could become of great importance for the millions of people currently requiring glucocorticoid therapy.

Hypotheses:

What are the effects of a two-week treatment with 7.5 mg prednisolone daily or 30 mg prednisolone daily, versus placebo, on:

1. Metabolic fluxes such as endogenous glucose production, rate of lipolysis and proteolysis?
2. Peripheral and hepatic insulin sensitivity?

This trial is linked to the PANTHEON I study, registered under ISRCTN78149983. Although these trials have the same interventions, the outcomes being looked at are different.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Ethics Committee of the VU University Medical Centre on the 11th October 2007 (ref: 2007/179).

Primary study design

Interventional

Study design

PANTHEON-II study is a randomised, placebo controlled, double blind, dose-response, parallel group intervention study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Metabolic syndrome

Interventions

The effects of a two-week treatment with either prednisolone 7.5 mg daily or prednisolone 30 mg daily, versus placebo, will be evaluated.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Prednisolone

Primary outcome(s)

To assess the effects of a two-week treatment with 7.5 or 30 mg prednisolone daily, compared to placebo, in healthy males and males with the metabolic syndrome on:

1. Metabolic fluxes of glucose-, fat- and protein metabolism (rates will be calculated using Steele's equation), measured at Day 14
2. Hepatic and peripheral insulin sensitivity (insulin sensitivity index measured during a two-step hyperinsulinaemic-euglycaemic clamp procedure), measured at Day 14

Key secondary outcome(s)

To assess the effects of a two-week treatment with 7.5 or 30 mg prednisolone daily, compared to placebo, in healthy males and males with the metabolic syndrome on:

1. Circulating biomarkers (plasma), measured at Day 14
2. Body composition, measured at Day 13
3. Blood pressure and haemodynamic parameters, measured at Day 13
4. Body fat distribution (Magnetic Resonance Imaging [MRI]), measured at Day 13
5. Molecular mechanisms underlying prednisolone effects, measured at Day 14

Completion date

01/09/2010

Eligibility

Key inclusion criteria

For all participants:

1. Written informed consent
2. Male caucasian
3. Smoking less than five cigarettes per day and capable of stopping during the trial period

For healthy participants:

1. healthy as determined by history taking, physical examination, laboratory examinations and Electrocardiogram (ECG):
 - 1.1. Aged 20 to 55 years

- 1.2. Body Mass Index (BMI) between 20 and 25 kg/m²
- 1.3. Fasting glucose less than 5.6 mmol/L and glucose less than 7.8 mmol/L at two hours after intake of 75 g glucose (Oral Glucose Tolerance Test [OGTT])

For participants with metabolic syndrome:

1. Aged 20 to 55 years
2. Waist circumference more than 94 cm
3. Three of following criteria:
 - 3.1. Triglycerides more than 1.7 mmol/L
 - 3.2. High Density Lipoprotein (HDL) cholesterol less than 1.03 mmol/L
 - 3.3. Blood pressure more than 130/85 mmHg
 - 3.4. Fasting glucose level less than 6.1 mmol/L and glucose less than 11.0 mmol/L at two hours after intake of 75 g glucose (OGTT)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Male

Key exclusion criteria

For all participants:

1. Idiosyncrasy/sensitivity to Glucocorticoids (GC)
2. GC use during the last three months prior to first study dose
3. Participation in an investigational drug trial within 90 days prior to the first dose
4. Donation of blood (more than 100 mL) within 90 days prior to the first dose
5. History of or current abuse of drugs or alcohol
6. Serious mental impairment or language problems, i.e., preventing to understand the study protocol/aim

For healthy participants:

1. Presence of a medical disorder
2. Medication use, except for incidental analgesic agents
3. First degree relative with type two diabetes mellitus
4. Performing intensive physical activity more than twice a week

For participants with metabolic syndrome:

1. Serious pulmonary, cardiovascular, hepatic (Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST] more than 3 x Upper Limit of Normal [ULN]) or renal disease (serum creatinine more than 135 mmol/L)
2. History of cardiovascular disease, such as myocardial infarction, cerebrovascular accident
3. Major psychiatric disorder
4. Depression
5. All diseases that induce changes in the Hypothalamic-Pituitary-Adrenal (HPA) axis
6. Malignant disease

7. All other relevant medical disorders that potentially interfere with this trial*

8. All medication interfering with study drug or interfering with study endpoints/hypotheses*

* the study physician and internist will make an individual assessment per subject whether he is eligible for inclusion

Date of first enrolment

01/09/2007

Date of final enrolment

01/09/2010

Locations

Countries of recruitment

Netherlands

Study participating centre

Department of Endocrinology/Diabetes Centre

Amsterdam

Netherlands

1081 HV

Sponsor information

Organisation

Vrije University Medical Centre (VUMC) (The Netherlands)

ROR

<https://ror.org/00q6h8f30>

Funder(s)

Funder type

Industry

Funder Name

Top Institute Pharma (TIP) (The Netherlands) - a collaborative structure consisting of industrial and academic research teams (www.tipharma.com)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2011		Yes	No
Results article	results	01/03/2013		Yes	No
Results article	results	01/07/2018	17/04/2019	Yes	No